Science & TechnologyImportant2025-10-23

CDSCO Strict Risk Classification Directive for Medical Devices

In News

What Happened

On October 23, 2025, the Central Drugs Standard Control Organization (CDSCO) issued a strict directive to State Licensing Authorities (SLAs) across India. The mandate requires SLAs to verify the risk classification of Class A and B medical devices and In Vitro Diagnostics (IVDs) against the Central Licensing Authority's (CLA) official master list before issuing any manufacturing licenses. This action halts a regulatory lapse where SLAs were wrongly approving unclassified or investigational devices as low-risk without central permission.

Why It Matters

This directive is crucial for preventing the misclassification of high-risk or unproven medical devices, thereby ensuring patient safety and product efficacy. It strictly enforces India's medical device regulatory framework, ensuring that local state approvals do not bypass necessary national-level scientific scrutiny.

Background

History & Context

Medical devices in India are governed by the Medical Devices Rules (MDR), 2017, framed under the Drugs and Cosmetics Act, 1940. Under MDR 2017, devices are categorized into four risk-based classes: A (low risk), B (low-moderate), C (moderate-high), and D (high risk). While the Central Licensing Authority (CLA) regulates higher-risk Class C and D devices, SLAs handle the manufacturing licenses for Class A and B devices. However, recent regulatory audits exposed that SLAs were improperly bypassing the CLA to approve new, unlisted, or investigational devices as low-risk.

What Changed

▶
Risk Classification Verification: BEFORE, SLAs sometimes issued manufacturing licenses for Class A and B devices based on localized assessments or manufacturer claims without central verification. NOW, SLAs must strictly verify the device's classification against the dynamic official list maintained by the CLA before granting any license.
▶
Approval of Unlisted Devices: BEFORE, unclassified devices or new In Vitro Diagnostics (IVDs) were occasionally treated as default low-risk devices and granted local licenses. NOW, if a device is not on the official CDSCO classification list, applicants must formally obtain its risk classification from the CLA first.
▶
Investigational Medical Devices: BEFORE, localized approvals for investigational medical devices could sometimes bypass mandatory central oversight due to SLA regulatory lapses. NOW, prior CLA approval is explicitly enforced as mandatory for all investigational medical devices and new IVDs under Chapter VII of the MDR, 2017.

Prelims Angle

NCERT Connection

This topic connects to the Class 12 Biology chapter 'Biotechnology and its Applications', specifically regarding the regulatory oversight of healthcare and diagnostic products. Just as the Genetic Engineering Appraisal Committee (GEAC) evaluates the safety of GMOs, the CDSCO/CLA evaluates the safety and clinical efficacy of biological diagnostics (like ELISA or PCR-based IVDs) to prevent public health hazards.

Practice Questions

Q1

With Reference To

With reference to the regulation of Medical Devices in India under the Medical Devices Rules, 2017, consider the following statements: 1. The manufacturing licenses for Class A (low risk) and Class B (low-moderate risk) medical devices are issued by the State Licensing Authorities (SLAs). 2. The master risk classification list of all medical devices is maintained and dynamically updated by the Central Licensing Authority (CLA). 3. Valid international certifications such as USFDA or CE markings legally exempt a medical device from requiring a CDSCO or SLA license in India. Which of the statements given above is/are correct?

Up next